公司资料
Aditxt, Inc. 股价、新闻与催化剂
- 股票代码:
- ADTX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.00 USD (-12.82%)
收盘价
最后更新: 2026年10月1日
89.6K USD
市值
股价为何变动
截至 2026年10月1日，ADTX 下跌 12.8%，收于 $0.0034。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Immune Health Technology Company
Aditxt develops and assembles technologies for immune monitoring, immune modulation, and precision diagnostics. Its business is organized through subsidiaries and licensed platforms rather than a single therapeutic franchise.
Adimune Immune Modulation
Adimune holds rights to nucleic-acid-based technology intended to retrain immune responses. The platform is being explored for autoimmune and other immune-mediated diseases through preclinical and development programs.
AditxtScore Immune Monitoring
AditxtScore is designed to provide a personalized profile of immune status. The technology evaluates antibody and cellular responses and can support monitoring of infection, vaccination, and immune health.
Pearsanta Precision Diagnostics
Pearsanta is developing mitochondrial-DNA-based biomarkers for diseases including prostate cancer and endometriosis. Earlier discovery work has also identified potential biomarker signatures in additional cancers.
Subsidiary and Transaction Model
Aditxt forms or acquires subsidiaries around distinct technologies and seeks outside financing, partnerships, and acquisitions to expand them. This structure creates multiple development tracks but also makes execution dependent on transaction completion and capital availability.
未来催化剂
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。